<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1118">
  <stage>Registered</stage>
  <submitdate>28/03/2006</submitdate>
  <approvaldate>28/03/2006</approvaldate>
  <nctid>NCT00310843</nctid>
  <trial_identification>
    <studytitle>Case-Control Viramune (Nevirapine) Toxicogenomics Study</studytitle>
    <scientifictitle>A Case-Control Toxicogenomics Study to Identify Unique Genetic Polymorphisms in Patients Who Have Experienced Symptomatic Hepatotoxicity or Severe Cutaneous Toxicity Within the First 8 Weeks of Nevirapine Therapy</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2005-004321-26</secondaryid>
    <secondaryid>1100.1452</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>HIV Infections</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Acquired immune deficiency syndrome (AIDS / HIV)</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Nevirapine

All study population - 


Treatment: drugs: Nevirapine
Patients with HIV-1 infection who have taken or are currently taking nevirapine

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Endpoints: relationship between nevirapine-related AEs and genetic polymorphisms loci: Drug metabolizing enzymes (e.g., cytochrome P450 isoforms) Drug transporters (e.g., MDR1 and OATP-C) Human Major Histocompatibility Complex region genes</outcome>
      <timepoint />
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Descriptive demographics comparing cases with matched controls in an attempt to link genetic polymorphisms associated with symptomatic hepatotoxicity or severe cutaneous toxicity (cases) to gender, race or other patient characteristics.</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Inclusion for Case

          1. Male or female patients &gt;=18 years of age with HIV-1 infection who experienced one or
             more of the following adverse reactions within the first 8 weeks of starting
             nevirapine therapy:

               -  Grade 3 or 4 LFT elevation (ALT or AST &gt; 5X ULN) and any symptom consistent with
                  clinical hepatitis (see Appendix 10.1)

               -  Acute liver failure secondary to nevirapine therapy*

               -  Functional group III or IV rash

               -  *Acute liver failure is defined as serious liver injury usually requiring
                  hospitalization that may lead to death or liver transplantation.

             Inclusion for Control

          2. Male or female patients &gt;=18 years of age with HIV-1 infection who have been exposed
             to nevirapine therapy for at least 18 weeks and who do not meet any of the case
             inclusion criteria</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Exclusion for Cases

          1. Patients with any hepatotoxicity or rash event which in the investigators judgement is
             not related to nevirapine use (ex. hepatotoxicity due to alcohol or other medicinal
             use or rash due to other medicinal use).

          2. Patients who began abacavir or TMP-SMX (trimethoprim/sulfamethoxazole) therapy 2 weeks
             or less prior to or up to 8 weeks after initiating nevirapine therapy.

          3. Patients with AST or ALT elevations &gt; 5 times the ULN (&gt;= Grade 3) just prior to the
             initiation of nevirapine therapy.

             Exclusion for Controls

          4. Patients who discontinued nevirapine before completing 18 weeks of dosing with 200
             mg/day for 2 weeks followed by 400 mg/day thereafter.

          5. Patients who developed functional group I, IIa or IIb rash within 18 weeks of starting
             nevirapine therapy, or any dermatologic condition that could plausibly be attributed
             to nevirapine.

          6. Patients with ALT or AST elevations &gt;2.5 X ULN (&gt;Grade 1) within 18 weeks of starting
             nevirapine therapy.

          7. Any hepatobiliary adverse event that could possibly be attributed to nevirapine.

          8. Patients who develop any systemic reaction attributable to nevirapine use during the
             first 18 weeks of nevirapine treatment such as flu-like symptoms, arthralgia, myalgia,
             or conjunctivitis.

             Exclusion for Cases and Controls

          9. Patients who have participated in the 2NN-Long-term Follow-up study (1100.1454)

         10. Patients with CD4 count 150 cells/mm3 prior to the initiation of nevirapine therapy
             (last available result measured 6 months prior to the initiation of nevirapine
             therapy).

         11. Evidence of acute co-infection with viral hepatitis.

         12. Patients taking prednisone, prednisolone, or immuno-modulatory medication within the
             first 8 weeks of nevirapine therapy.

         13. Patients who are unwilling to provide blood samples for DNA testing.

         14. Patients who did not sign informed consent and or authorization to release protected
             health information per local requirements.

         15. Patients without available liv</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing>Retrospective</timing>
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate />
    <actualstartdate>1/02/2006</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>889</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD,VIC</recruitmentstate>
    <hospital>1100.1452.61004 Boehringer Ingelheim Investigational Site - Darlinghurst</hospital>
    <hospital>1100.1452.61005 Boehringer Ingelheim Investigational Site - DarlingHurst</hospital>
    <hospital>1100.1452.61006 Boehringer Ingelheim Investigational Site - Darlinghurst</hospital>
    <hospital>1100.1452.61003 Boehringer Ingelheim Investigational Site - Miami</hospital>
    <hospital>1100.1452.61002 Boehringer Ingelheim Investigational Site - Carlton</hospital>
    <hospital>1100.1452.61008 Boehringer Ingelheim Investigational Site - Melbourne</hospital>
    <hospital>1100.1452.61001 Boehringer Ingelheim Investigational Site - South Yarra</hospital>
    <postcode> - Darlinghurst</postcode>
    <postcode> - DarlingHurst</postcode>
    <postcode> - Miami</postcode>
    <postcode> - Carlton</postcode>
    <postcode> - Melbourne</postcode>
    <postcode> - South Yarra</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Alabama</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Colorado</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Connecticut</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maryland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Capital Federal</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Rosario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>British Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Bordeaux</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Lyon cedex 2</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Lyon Cedex 3</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Lyon cedex 3</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Lyon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Nantes cedex 1</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Nantes</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris cedex 12</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris cedex 20</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Toulouse cedex 9</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Toulouse</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Tourcoing cedex</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Vandoeuvre les Nancy</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Berlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Bochum</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Bonn</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Düsseldorf</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Essen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Frankfurt am Main</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Hamburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>München</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Ulm</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Würzburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Amsterdam</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Badalona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>L'Hospitalet de Llobregat</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Sevilla</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Kaohsiung</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Taichung</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Taipei</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Thailand</country>
      <state>Bangkok</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Thailand</country>
      <state>Khon Kaen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Birmingham</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Brighton</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Coventry</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Manchester</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Plaistow, London</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Boehringer Ingelheim</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>Attempt to identify genetic polymorphisms in interrogated pathways which may be associated
      with symptomatic hepatotoxicity or severe cutaneous toxicity observed in case patients within
      the first 8 weeks of nevirapine therapy.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00310843</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Boehringer Ingelheim</name>
      <address>Boehringer Ingelheim</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>